Vertex Pharma (VRTX) Tops Q2 EPS by 11c; Raises Outlook
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $466.79 --0%
Revenue Growth %: +8.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +8.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.60, $0.11 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.2 billion versus the consensus estimate of $2.13 billion.
GUIDANCE:
Vertex Pharma raises FY2022 revenue to $8.6-8.8 billion, versus the consensus of $8.58 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
